Submit Deal

CHIMERIX

HQ - Durham

Summary

Chimerix is a biopharmaceutical company that focuses on researching and developing medicines for serious diseases, particularly in areas such as oncology (cancer) and viral infections.

Deals Overview

Total Deals3

Valued Deals3

Total Value£ 1.07 B

Avg. Deal Size£ 356 M

Market Context

Senior Management

Mike Sherman
CEO
Michelle LaSpaluto
Communications Director

Sort

08 Jan 2021|United States|Biotechnology

Target: ONCOCEUTICS

Bidder: CHIMERIX

7 Service Providers

3 Target | 4 Bidder

16 Dealmakers

1 Target | 15 Bidder

£ 57 M

Value

16 May 2022|United States|Pharmaceuticals

Target: TEMBEXA

Bidder: EMERGENT BIOSOLUTIONS INC

6 Service Providers

2 Bidder | 4 Vendor

23 Dealmakers

7 Bidder | 16 Vendor

£ 275 M

Value

05 Mar 2025|United States|Pharmaceuticals

Target: CHIMERIX

Bidder: JAZZ PHARMACEUTICALS

11 Service Providers

7 Target | 4 Bidder

53 Dealmakers

31 Target | 22 Bidder

£ 734 M

Value